|
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4641-4647.
Prepublished online as a Blood First Edition Paper on February 13, 2007; DOI 10.1182/blood-2006-10-051342.
 Previous Article | Next Article 
Submitted October 30, 2006
Accepted February 2, 2007
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia:
an international retrospective study
Henrik Hasle*, Todd A Alonzo, Anne Auvrignon, Catherine Behar, Myron Chang, Ursula Creutzig, Alexandra Fischer, Erik Forestier, Alcira Fynn, Oskar A Haas, Jochen Harbott, Christine J Harrison, Nyla A Heerema, Marry M van den Heuvel-Eibrink, Gertjan J. L. Kaspers, Franco Locatelli, Peter Noellke, Sophia Polychronopoulou, Yaddanapudi Ravindranath, Bassem Razzouk, Dirk Reinhardt, Natalia N Savva, Batia Stark, Stefan Suciu, Ichiro Tsukimoto, David K Webb, Dorota Wojcik, William G Woods, Martin Zimmermann, Charlotte M Niemeyer, and Susana C Raimondi
Dept of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Children's Oncology Group, University of Southern California, Los Angeles, CA, United States
French Leucemie Aique Myeloide Enfant (LAME), Hopital Trousseau, Paris, France
Hopital Americain, Reims, France
Pediatric Oncology Group Statistical Office, Gainesville, FL, United States
AML-BFM trials, Pediatric Hematology/Oncology, University Hospital Munster, Germany
Dept of Pediatrics & Adolescent Medicine, University of Freiburg, Freiburg, Germany
Dept of Clinical Science, Umea University Hospital, Umea, Sweden
Servicio de Hematologia, Hospital de Ninos S.M.Ludovica, La Plata, Argentina
CCRI & St. Anna Children's Hospital, Vienna, Austria
Dept of Pediatric Hematology & Oncology, University of Giessen, Germany
Leukaemia Research Fund Group, University of Southampton, Southampton, United Kingdom
Dept of Pathology, Ohio State University, Columbus, OH, United States
Dutch Childhood Oncology Group (DCOG), & Dept of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus Univ. Medical Center, Rotterdam, Netherlands
AML committee I-BFM-SG, Dept of Pediatric Hematology/Oncology, VU University Medical Center, Amsterdam, Netherlands
IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Dept of Pediatric Hematology/Oncology, Aghia Sophia Children's Hospital, Athens, Greece
Wayne State University, Dept of Pediatrics, Children's Hospital of Michigan, Detroit, MI, United States
St Jude Children's Researh Hospital, Memphis, TN, United States
AML-BFM trials, Pediatric Hematology/Oncology, Medical School Hanover, Germany
Dept of Hematology, National Research Center for Pediatric Oncology and Hematology, Minsk, Belarus
Pediatric Hematology Oncology, Schneider Children's Center of Israel, Petah-Tikva, Israel
EORTC, European Organization for Research and Treatment of Cancer, Brussels, Belgium
Dept of Pediatrics, Toho University School of Medicine, Tokyo, Japan
Great Ormond Street Hospital for Children, London, United Kingdom
Dept of Pediatric Bone Marrow Transplantation, Oncology, & Hematology, Wroclaw Medical University, Wroclaw, Poland
Children's Healthcare of Atlanta/Emory University, Atlanta, GA, United States
Dept of Pathology, St Jude Children's Research Hospital, Memphis, TN, United States
* Corresponding author; email: hasle{at}dadlnet.dk.
Monosomy 7 [-7] and deletion 7q [del(7q)] are rare in childhood AML. We retrospectively collected data on 258 children with AML or RAEB-T and -7 or del(7q) with or without other cytogenetic aberrations [± other]. Karyotypes included -7 (n=90), -7 other (n=82), del(7q) (n=21), and del(7q) other (n=65). Complete remission (CR) was achieved in fewer patients with -7 ± other compared with del(7q) ± other (61% vs. 89%; p<0.001). Overall, the 5-year-survival rate was 39% (SE 3%). Survival was superior in del(7q) ± other compared with -7 ± other (51% vs. 30%, p<0.01). Cytogenetic aberrations considered favorable in AML [t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q22;q21), t(9;11)(p22;q23)] (n=24) were strongly associated with del(7q) and a higher 5-year survival rate compared with del(7q) without favorable cytogenetics (75% vs. 46%, p=0.03). Patients with -7 and inv(3), -5/del(5q), or +21 had a 5-year survival rate of 5%. Stem cell transplantation analyzed as time-dependent variable had no impact on overall survival. However, patients not achieving CR had a 31% survival rate after stem cell transplantation. Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having major prognostic impact which should be reflected in future risk-group stratification.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. V. Balgobind, S. C. Raimondi, J. Harbott, M. Zimmermann, T. A. Alonzo, A. Auvrignon, H. B. Beverloo, M. Chang, U. Creutzig, M. N. Dworzak, et al.
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
Blood,
September 17, 2009;
114(12):
2489 - 2496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica,
January 1, 2009;
94(1):
102 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
